Immune cells in lymph nodes predicting immunotherapy response for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This study examines specific immune cell patterns in lymph nodes to predict how well PD-1 immunotherapy (a type of cancer-fighting treatment) will work for advanced or recurrent esophageal cancer. The goal is to better understand which patients will benefit most from this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have esophageal cancer confirmed by biopsy (tissue sample)
- Your cancer is stage 4 (advanced) or has come back after previous treatment
- Your doctor plans to treat you with PD-1 immunotherapy (a specific type of immune-boosting drug)
- You are in good enough health to tolerate treatment (ECOG score 0–2, meaning you can do most normal activities)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a specific marker in lymph nodes to predict whether PD-1 immunotherapy (a type of cancer-fighting immune treatment) will work well before surgery in esophageal cancer patients. Understanding this marker may help doctors choose the best treatment plan.
This study is for people with lung or esophageal cancer who will receive immunotherapy (drugs that help your immune system fight cancer). The researchers want to find markers in your blood and tumor that can predict how well the treatment will work.
This trial studies a personalized approach to palliative care for people with advanced or recurrent esophageal cancer who are being treated with immunotherapy. It aims to improve quality of life and symptom management.
This Phase 3 trial tests whether adding a PD-1 medicine (sintilimab) to standard chemo-radiation before surgery improves outcomes for locally advanced esophageal squamous cell cancer. It may help by strengthening the immune response while shrinking the tumor before an operation.
This study uses an “immune indicator model” to help predict how well a PD-1 antibody (a cancer-fighting immune drug) works when combined with chemotherapy for stage IV esophageal squamous cell cancer. If you qualify, you receive the treatment and the researchers also look for immune-related signs that may explain who benefits most.
This trial tests a treatment for locally advanced esophageal cancer. You'll receive chemoradiation (chemo plus radiation) followed by a maintenance drug (a PD-1 inhibitor) to help prevent the cancer from coming back.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.